Literature DB >> 23617857

Steps physicians report taking to reduce diversion of buprenorphine.

Amy Yang1, Cynthia L Arfken, Chris-Ellyn Johanson.   

Abstract

BACKGROUND AND OBJECTIVES: Physicians are challenged to effectively treat opioid dependent patients while minimizing diversion of potentially abusable medications, such as buprenorphine. The present study was designed to obtain information on steps physicians report taking to reduce diversion of buprenorphine.
METHOD: National quarterly surveys from 2008 to 2009 of qualified physicians who have prescribed buprenorphine were analyzed (N = 2,330). One part of the survey queried physicians about what steps they had taken to reduce abuse and diversion of buprenorphine from a pre-specified list of 12 steps. Other parts of the survey included questions on the physicians' training and experience.
RESULTS: Physicians reported taking a mean of 4.4 steps. Longer experience prescribing buprenorphine, more buprenorphine-related educational training, and concern about diversion as a limitation on using buprenorphine for maintenance were associated with higher number of steps taken. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Physicians are currently taking multiple steps to reduce diversion. Future research needs to verify if these steps are effective or are instead reducing access to treatment.
Copyright © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617857     DOI: 10.1111/j.1521-0391.2012.00335.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  10 in total

1.  Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens; Jamie L Studts
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

2.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

3.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

4.  A mixed methods study of provider factors in buprenorphine treatment retention.

Authors:  Alex K Gertner; Hannah Margaret Clare; Byron J Powell; Allison R Gilbert; Hendree E Jones; Pam Silberman; Christopher M Shea; Marisa Elena Domino
Journal:  Int J Drug Policy       Date:  2022-05-06

Review 5.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

6.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

7.  US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Lewei Allison Lin; Sharon L Walsh; Jamie L Studts
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.852

8.  Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.

Authors:  Margo E Godersky; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Jane M Simoni; Judith I Tsui
Journal:  Addict Sci Clin Pract       Date:  2019-03-13

9.  MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.

Authors:  Zev Schuman-Olivier; Jacob T Borodovsky; Jackson Steinkamp; Qays Munir; Kyle Butler; Mary Ann Greene; Jonah Goldblatt; Hai Yi Xie; Lisa A Marsch
Journal:  Addict Sci Clin Pract       Date:  2018-09-24

10.  Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan.

Authors:  Jia-Shin Chen
Journal:  Sociol Health Illn       Date:  2019-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.